The Study of The Treatment of Postoperative Adjuvant Apatinib vs. TACE in Hepatocellular Carcinoma Patients

Inclusion Criteria: 1. Age: ≥18 years old; 2. HCC diagnosed by histopathology or cytology (including pathological margin positive lesions, residual positive lesions after DSA angiography, combined vascular tumor thrombus and/or biliary tumor thrombus, pathologically confirmed lymph node metastasis, and liver The tumor ruptured, adjacent organs were invaded, the number of tumors was ≥ 3, AFP did not fall to normal range at 2 months after operation, and pathologically confirmed vegf + or patients with microvascular invasion. 3. Child-Pugh Liver Function Rating: Grade A or better Grade B (≤ 7 points); 4. ECOG PS score: 0-1 points; 5. Expected survival period ≥ 12 weeks; 6. The normal function of the major organs is the following: (1) Blood tests: HB≥90 g/L; ANC≥1.5×109/L; PLT≥60×109/L; (2) Biochemical tests: ALB ≥29 g/L; ALT and AST\<2.5ULN; TBIL ≤ 2ULN; Creatinine ≤1.5ULN; (Child-Pugh can only have 2 points for both albumin and bilirubin) 7. Women of childbearing age must undergo a pregnancy test within 7 days prior to enrollment; 8. Subjects voluntarily joined the study, signed informed consent, and adhered well to follow-up. Exclusion Criteria: 1. Have received systematic treatment in the past; 2. Hepatobiliary cell carcinoma and mixed cell carcinoma and fibrous lamellar cell carcinoma are known; in the past (within 5 years) or with other untreated malignant tumors, except for cured skin basal cell carcinoma and cervical carcinoma in situ; 3. Patients who are preparing for liver transplantation (except those who have previously undergone liver transplantation); 4. Ascites with clinical symptoms, which require therapeutic paracentesis or drainage; 5. People with high blood pressure who are unable to fall within the normal range after treatment with antihypertensive drugs (systolic blood pressure\>140 mmHg, diastolic blood pressure\>90 mmHg); 6. Arrhythmia with grade II or higher myocardial ischemia or myocardial infarction and poor control (including QMS interval men ≥450 ms, women ≥470 ms); 7. In accordance with NYHA criteria III-IV heart failure or cardiac ultrasound examination: LVEF (left ventricular ejection fraction) \<50%; 8. Has a variety of factors that affect oral medications (such as inability to swallow, chronic diarrhea, and intestinal obstruction, which significantly affect drug intake and absorption); 9. In the past 6 months, there was a history of digestive tract bleeding or a clear tendency to gastrointestinal bleeding. For example, esophageal varices, local active ulcer lesions, fecal occult blood ≥ (++) may not enter the group. If fecal occult blood (+) requires gastroscopy; 10. Abdominal fistula, gastrointestinal perforation or abdominal abscess occurred within 28 days before participating in this study; 11. Coagulation abnormalities (INR\> 1.5 or prothrombin time (PT)\> ULN + 4 seconds) with a tendency to hemorrhage or receiving thrombolytic or anticoagulant therapy; 12. Patients with central nervous system metastases or known brain metastases have occurred; 13. Patients with objective evidence of previous and current history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, and severe impaired lung function; 14. Urine routine showed urinary protein ≥ ++ or confirmed 24-hour urinary protein quantification\> 1.0 g; 15. Was treated with potent CYP3A4 inhibitors within 7 days before participating in the study or was treated with potent CYP3A4 inducer within 12 days prior to study participation; 16. Pregnancy or breastfeeding women; those with fertility who are unwilling or unable to take effective contraceptive measures; 17. There is a history of mental illness or abuse of psychotropic substances; 18. Patients with bone metastases who have received palliative radiotherapy (radiotherapy area\> 5% bone marrow area) within 4 weeks before participating in the study; 19. Joint HIV-infected patients.